Loading
Enhertu shrank about four in ten heavily pretreated HER2-positive bowel cancers, including ones that had already stopped responding to other HER2 drugs.
DESTINY-CRC02, trial NCT04744831 sponsored by Daiichi Sankyo and AstraZeneca and reported in 2023, showed that trastuzumab deruxtecan shrinks about four in ten heavily pretreated HER2-positive metastatic colorectal cancers, including ones that had already stopped responding to other HER2 drugs. It randomised 122 patients to 5.4 or 6.4 mg/kg, with confirmed response rates of 37.8 and 27.5 percent respectively, responses regardless of prior HER2 therapy or RAS status, and the data supported the 2024 tumour-agnostic HER2 IHC 3+ accelerated approval, which covers colorectal cancer at the lower dose. OnCo links it to colorectal cancer, HER2 as a target, trastuzumab deruxtecan and the tumour-agnostic approval term, and the result is consistent with DESTINY-CRC01. Without a randomised comparison, whether the drug improves survival over other HER2 combinations is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
This is the paper Europe PMC returns for registry id NCT04744831 with the most citations, so it is the natural first reading for anyone following the DESTINY-CRC02 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
The antibody-drug conjugate route into HER2-positive colorectal cancer, extended by DESTINY-CRC02 at a lower dose; interstitial lung disease is the class risk that defines how the drug is monitored.
It is the threshold behind the colorectal HER2 approvals: the more-than-50% rule, rather than the 10% used in gastric cancer, is what a pathologist applies when a bowel cancer is called HER2-positive.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares DESTINY-CRC01, MOUNTAINEER-03, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, HER2-amplified colorectal cancer.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), HER2.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), HER2.